Models | Subgroup | Study number (case/control) | OR (95% CI) | z | P |
---|---|---|---|---|---|
Allelic model (G vs. A) | Lung cancer | 19 (5004/9162) | 0.95 (0.8–1.02) | 1.42 | 0.155 |
LSCC | 3 (878/19,47) | 0.91 (0.77–1.08) | 1.08 | 0.282 | |
NSCLC | 3 (928/1766) | 1.00 (0.75–1.34) | < 0.01 | 0.999 | |
LA | 3 (968/1947) | 0.98 (0.86–1.11) | 0.35 | 0.729 | |
Breast cancer | 6 (2530/2940) | 1.00 (0.83–1.20) | < 0.01 | 0.998 | |
Digestive system cancer | 18 (4038/6811) | 1.13 (0.96–1.34) | 1.48 | 0.138 | |
Esophageal cancer | 10 (2515/4002) | 1.06 (0.82–1.39) | 0.47 | 0.642 | |
ESCC | 4 (1136/2239) | 1.09(0.76–1.56) | 0.45 | 0.654 | |
Gastric cancer | 4 (828/1495) | 1.14 (0.83–1.58) | 0.82 | 0.412 | |
Colorectal cancer | 3 (593/1021) | 1.20 (1.03–1.40) | 2.31 | 0.021 | |
Reproductive system cancer | 5 (1429/1756) | 1.10 (1.98–1.24) | 1.54 | 0.123 | |
Endometrial cancer | 3 (1182/1244) | 1.09 (0.89–1.33) | 0.86 | 0.390 | |
Head and neck cancer | 4 (886/2289) | 1.08 (0.96–1.22) | 1.34 | 0.179 | |
Skin cancer | 6 (3874/3826) | 1.17 (1.09–1.25) | 4.60 | < 0.001 | |
Skin BCC | 3 (1852/1669) | 1.18 (1.07–1.31) | 3.23 | 0.001 | |
Carrier model (G vs. A) | Lung cancer | 19 (5004/9162) | 0.97 (0.92–1.03) | 0.94 | 0.345 |
LSCC | 3 (878/19,47) | 0.94 (0.83–1.08) | 0.87 | 0.386 | |
NSCLC | 3(928/1766) | 0.97 (0.84–1.12) | 0.42 | 0.675 | |
LA | 3 (968/1947) | 0.99 (0.86–1.14) | 0.14 | 0.891 | |
Breast cancer | 6 (2530/2940) | 1.00 (0.91–1.10) | 0.03 | 0.977 | |
Digestive system cancer | 18 (4038/6811) | 1.09 (1.02–1.17) | 2.49 | 0.013 | |
Esophageal cancer | 10 (2515/4002) | 1.09 (1.00–1.19) | 2.00 | 0.046 | |
ESCC | 4 (1136/2239) | 1.06 (0.93–1.20) | 0.88 | 0.379 | |
Gastric cancer | 4 (828/1495) | 1.04 (0.89–1.20) | 0.47 | 0.637 | |
Colorectal cancer | 3 (593/1021) | 1.12 (0.94–1.33) | 1.29 | 0.199 | |
Reproductive system cancer | 5 (1429/1756) | 1.07 (0.95–1.21) | 1.15 | 0.251 | |
Endometrial cancer | 3 (1182/1244) | 1.08 (0.94–1.24) | 1.07 | 0.285 | |
Head and neck cancer | 4 (886/2289) | 1.07 (0.93–1.22) | 0.93 | 0.355 | |
Skin cancer | 6 (3874/3826) | 1.12 (1.03–1.21) | 2.82 | 0.005 | |
Skin BCC | 3 (1852/1669) | 1.13 (1.01–1.26) | 2.05 | 0.040 | |
Homozygotic model (GG vs. AA) | Lung cancer | 19 (5004/9162) | 0.87 (0.77–0.99) | 2.15 | 0.032 |
LSCC | 3 (878/19,47) | 0.81 (0.59–1.12) | 1.27 | 0.206 | |
NSCLC | 3 (928/1766) | 0.91 (0.59–1.41) | 0.42 | 0.677 | |
LA | 3 (968/1947) | 0.92 (0.71–1.18) | 0.66 | 0.512 | |
Breast cancer | 6 (2530/2940) | 1.01 (0.70–1.45) | 0.06 | 0.954 | |
Digestive system cancer | 18 (4038/6811) | 1.35 (0.96–1.89) | 1.72 | 0.086 | |
Esophageal cancer | 10 (2515/4002) | 1.25 (0.74–2.11) | 0.82 | 0.410 | |
ESCC | 4 (1136/2239) | 1.31 (0.61–2.81) | 0.69 | 0.489 | |
Gastric cancer | 4 (828/1495) | 1.13 (0.67–1.93) | 0.46 | 0.648 | |
Colorectal cancer | 3 (593/1021) | 1.68 (1.15–2.44) | 2.70 | 0.007 | |
Reproductive system cancer | 5 (1429/1756) | 1.14 (0.90–1.44) | 1.05 | 0.295 | |
Endometrial cancer | 3 (1182/1244) | 1.12 (0.78–1.60) | 0.61 | 0.541 | |
Head and neck cancer | 4 (886/2289) | 1.09 (0.85–1.41) | 0.67 | 0.503 | |
Skin cancer | 6 (3874/3826) | 1.36 (1.17–1.57) | 4.11 | < 0.001 | |
Skin BCC | 3 (1852/1669) | 1.40 (1.03–1.89) | 2.17 | 0.030 |